viewLiberty Global

UK watchdog calls for review of £31bn merger between O2 and Virgin Media

The Competition and Markets Authority wants to conduct the review rather than the EU's competition arm

Liberty Global -
Virgin Media has a large cable network

The UK competition watchdog has asked the European Commission (EC) to refer the planned £31bn merger between O2 and Virgin Media for a full UK investigation.

The tie-up, which was confirmed by O2's Spanish owner Telefonica and Virgin's US parent Liberty Global in May, comes under the remit of the EC's antitrust commissioner but a review can be transferred to the UK’s Competition and Markets Authority (CMA).

The CMA said it should investigate the deal “given its potential impact on competition in several retail and wholesale telecommunication markets in the UK".

READ: New Virgin Media-O2 giant will reshape the UK telecoms industry

The legal requirements for the case to be transferred have been met, the CMA said.

“We’ve sent a formal request to the European Commission to review the proposed deal between Virgin and O2,” CMA chief executive Andrea Coscelli said in a statement.

“Ultimately, this is a decision for the EC, but as the merger will only impact UK consumers – and any effects would only be felt after the end of the transition period – it is only right for the CMA to request it back.”

The combined O2-Virgin, with around 32mln direct customers as well as 34mln non-direct clients such as Tesco Mobile, would be a big rival for BT Group PLC (LON:BT.A), which owns EE, as well as Vodafone PLC (LON:VOD), Talktalk Telecom Group PLC (LON:TALK), Sky and Three.

TalkTalk received a preliminary offer from major shareholder Toscafund on Thursday.

Quick facts: Liberty Global


Price: 28.75 USD

Market Cap: $15.97 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


BioVaxys preps for Phase 1 study as vaccine manufacturing partner reaches...

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine. Kovan says the Lyon,...

1 day, 11 hours ago

2 min read